268557-49-9

Usage

Uses

Used in Pharmaceutical Industry:
2-(Acetylamino)-2-[2-(4-octylphenyl)-2-oxoethyl]-propanedioic acid 1,3-diethyl ester is used as a reactant for the preparation of immunosuppressive agents, specifically FRY-720 (F805000). Its unique structure allows it to play a crucial role in the synthesis of these agents, which are essential for managing the immune response in various medical conditions.
The compound's ability to be used in the production of immunosuppressive agents highlights its potential in the pharmaceutical industry, where it can contribute to the development of new drugs and therapies for a range of health issues. Its specific application in the synthesis of FRY-720 (F805000) demonstrates its importance in the field of immunosuppression, which is a critical area of research and treatment for conditions such as autoimmune diseases and organ transplantation.

Upstream product

• 64068-76-4 α-bromomethyl p(n-octyl)phenyl cetone 
• 1068-90-2 2-acetylaminomalonic acid diethyl ester 
• 141-52-6 sodium ethanolate 
• 10541-56-7 4-n-octylacetophenone 
• 111-64-8 n-octanoic acid chloride 
• 71-43-2 benzene 
• 1674-37-9 n-octanophenone 
• 13433-00-6 diethyl aminomalonate hydrochloride 
• 2189-60-8 Octylbenzene 

Downstream Products

• 162358-08-9 diethyl 2-acetamido-2-[2-(4-octylphenyl)ethyl]malonate 
• 949014-01-1 [1-(di-tert-butoxy-phosphoryloxymethyl)-3-(4-octyl-phenyl)-propyl]-carbamic acid tert-butyl ester 
• 949081-33-8 [1-(di-tert-butoxy-thiophosphoryloxymethyl)-3-(4-octyl-phenyl)-propyl]-carbamic acid tert-butyl ester 
• 177260-59-2 2-amino-4-(4-octylphenyl)butanol 
• 596820-24-5 [1-hydroxymethyl-3-(4-octyl-phenyl)-propyl]-carbamic acid tert-butyl ester 
• 249289-10-9 N-(1-hydroxy-2-(hydroxymethyl)-4-(4-octylphenyl) butan-2-yl) acetamide 
• 162359-55-9 fingolimod 
• 162361-49-1 3-amino-3-(hydroxymethyl)-1-(4-octylphenyl)butane-1,4-diol 
• 1620230-20-7 N-[1,1-bis(hydroxymethyl)-3chloro-(4-octylphenyl)propyl]acetamide 
• 1620230-21-8 N-[1,1-bis(hydroxymethyl)-3-(4-octylphenyl)allyl]acetamide 
• 1620230-22-9 2-amino-2-[2-(4-octylphenyl)vinyl]propane-1,3-diol 

Relevant academic research and scientific papers

Synthesis and evaluation of fluorinated fingolimod (FTY720) analogues for sphingosine-1-phosphate receptor molecular imaging by positron emission tomography

Sphingosine-1-phosphate (S1P) is a lysophospholipid that evokes a variety of biological responses via stimulation of a set of cognate G-protein coupled receptors (GPCRs): S1P1-S1P5. S1P and its receptors (S1PRs) play important roles in the immune, cardiovascular, and central nervous systems and have also been implicated in carcinogenesis. Recently, the S1P analogue Fingolimod (FTY720) has been approved for the treatment of patients with relapsing multiple sclerosis. This work presents the synthesis of various fluorinated structural analogues of FTY720, their in vitro and in vivo biological testing, and their development and application as [18F]radiotracers for the study of S1PR biodistribution and imaging in mice using small-animal positron emission tomography (PET).

INTERMEDIATES AND PROCESS FOR THE PREPARATION OF HIGH PURITY FINGOLIMOD HYDROCHLORIDE

The present invention relates to a simple and commercially feasible preparation of Fingolimod hydrochloride with high purity of greater than 99.9%. The.present invention also provides novel intermediates for the preparation of Fingolimod Hydrochloride of Formula 1.

NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES

The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.

NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES

The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.

Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors

Phosphothioates may provide metabolic stability when compared to their phosphate counterparts, while retaining the potency and efficacy as agonists at sphingosine-1-phosphate (S1P) G-protein coupled receptors. Unlike their phosphate precursors, phosphothi

ORALLY AVAILABLE SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS AND ANTAGONISTS

The present invention relates to S1P analogs that have activity as S1Preceptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R11 is C5-C18 alkyl or C5-C18 alkenyl; Q is selected from the group consisting of C3-C6 optionally substituted cycloalkyl, C3-C6 optionally substituted heterocyclic, C3-C6 optionally substituted aryl C3-C6 optionally substituted heteroaryl and; R2 is selected from the group consisting of H, C1-C4 alkyl, (C1-C4 alkyl)OH and (C1-C4 alkyl)NH2; R23 is H or C1-C4 alkyl, and R15 is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.

Production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols

Disclosed is a process for the production of 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diols.

A new efficient synthesis of the immunosuppressive agent FTY-720

A new efficient five-step synthesis of the immunosuppressive agent FTY- 720 is described.